PMCB vs. CVM, AVRO, ENTX, CRIS, TSBX, GNTA, DYAI, TARA, CDTX, and LENZ
Should you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include CEL-SCI (CVM), AVROBIO (AVRO), Entera Bio (ENTX), Curis (CRIS), Turnstone Biologics (TSBX), Genenta Science (GNTA), Dyadic International (DYAI), Protara Therapeutics (TARA), Cidara Therapeutics (CDTX), and LENZ Therapeutics (LENZ). These companies are all part of the "biological products, except diagnostic" industry.
CEL-SCI (NYSE:CVM) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 16.2% of CEL-SCI shares are held by company insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
CEL-SCI has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
CEL-SCI's return on equity of -9.69% beat PharmaCyte Biotech's return on equity.
CEL-SCI and PharmaCyte Biotech both received 0 outperform votes by MarketBeat users.
CEL-SCI is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, PharmaCyte Biotech had 2 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for PharmaCyte Biotech and 0 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.94 beat PharmaCyte Biotech's score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the news media.
Summary
PharmaCyte Biotech beats CEL-SCI on 7 of the 10 factors compared between the two stocks.
Get PharmaCyte Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PharmaCyte Biotech Competitors List
Related Companies and Tools
